发明名称 Unitary pharmaceutical dosage form
摘要 In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.
申请公布号 US9018192(B2) 申请公布日期 2015.04.28
申请号 US201314050714 申请日期 2013.10.10
申请人 Bristol-Myers Squibb & Gilead Sciences, Inc. 发明人 Dahl Terrence C.;Hussain Munir A.;Lipper Robert A.;Jerzewski Robert L.;Menning Mark M.;Oliyai Reza;Yang Taiyin
分类号 A61K31/683;A61K31/536;A61K31/513;A61K31/535;A61K31/522;A61K31/675;A61K9/20;A61K9/24;A61K31/551 主分类号 A61K31/683
代理机构 Cooley LLP 代理人 Cooley LLP
主权项 1. A method comprising administering to a patient in need of antiviral therapy a composition comprising a unitary dosage form comprising tenofovir DF in a first compartment and a surfactant and efavirenz in a second compartment, wherein the first and second compartments are physically discrete but associated with and in physical contact with one another, and further comprising emtricitabine, and wherein the antiviral therapy is anti-HIV therapy.
地址 Foster City CA US